Download Image
    
Share
  
Post
Siltuximab for COVID-19
1 study with 149 patients
Hospital Icon Control
Hospital Icon Siltuximab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Siltuximab studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -64% Mortality -64% RCTs -64% Late -64% Favorssiltuximab Favorscontrol
Dec 31
2021
 Declercq et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00377-5 Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
64% higher mortality (p=0.27). RCT 342 hospitalized COVID-19 patients with hypoxia and signs of cytokine release syndrome in Belgium, showing no significant difference in time to clinical improvement, mortality, or other outcomes with IL-1 blockade (anakinra) or IL-6 b..
May 24
2021
 Gritti et al., Leukemia, doi:10.1038/s41375-021-01299-x Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
Prospective observational study of 30 hospitalized COVID-19 patients requiring ventilatory support in Italy, showing improved ventilatory status and survival with siltuximab treatment, particularly with the reduction of IL-8 and PTX3 leve..